Abstract
The ability of antisera raised against a candidate Japanese encephalitis virus (JEV) vaccine, ChimeriVax™-JE, and the currently licensed vaccine, JE-VAX®, to protect against strains of JEV representing the four major genotypes was assessed. Neutralization assays and passive protection studies in mice showed that greatest protection was provided against strains of genotypes II and III, although some protection was also afforded against genotypes I and IV strains. ChimeriVax™-JE stimulated protection that was comparable or superior to the JE-VAX® control.
Original language | English (US) |
---|---|
Pages (from-to) | 3722-3726 |
Number of pages | 5 |
Journal | Vaccine |
Volume | 22 |
Issue number | 27-28 |
DOIs | |
State | Published - Sep 9 2004 |
Fingerprint
Keywords
- ChimeriVax™-JE
- Genotype
- Japanese encephalitis virus
ASJC Scopus subject areas
- Immunology
- Microbiology
- Virology
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- veterinary(all)
Cite this
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine. / Beasley, David; Li, Li; Suderman, Miguel T.; Guirakhoo, Farshad; Trent, Dennis W.; Monath, Thomas P.; Shope, Robert E.; Barrett, Alan.
In: Vaccine, Vol. 22, No. 27-28, 09.09.2004, p. 3722-3726.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine
AU - Beasley, David
AU - Li, Li
AU - Suderman, Miguel T.
AU - Guirakhoo, Farshad
AU - Trent, Dennis W.
AU - Monath, Thomas P.
AU - Shope, Robert E.
AU - Barrett, Alan
PY - 2004/9/9
Y1 - 2004/9/9
N2 - The ability of antisera raised against a candidate Japanese encephalitis virus (JEV) vaccine, ChimeriVax™-JE, and the currently licensed vaccine, JE-VAX®, to protect against strains of JEV representing the four major genotypes was assessed. Neutralization assays and passive protection studies in mice showed that greatest protection was provided against strains of genotypes II and III, although some protection was also afforded against genotypes I and IV strains. ChimeriVax™-JE stimulated protection that was comparable or superior to the JE-VAX® control.
AB - The ability of antisera raised against a candidate Japanese encephalitis virus (JEV) vaccine, ChimeriVax™-JE, and the currently licensed vaccine, JE-VAX®, to protect against strains of JEV representing the four major genotypes was assessed. Neutralization assays and passive protection studies in mice showed that greatest protection was provided against strains of genotypes II and III, although some protection was also afforded against genotypes I and IV strains. ChimeriVax™-JE stimulated protection that was comparable or superior to the JE-VAX® control.
KW - ChimeriVax™-JE
KW - Genotype
KW - Japanese encephalitis virus
UR - http://www.scopus.com/inward/record.url?scp=4143125552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4143125552&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2004.03.027
DO - 10.1016/j.vaccine.2004.03.027
M3 - Article
C2 - 15315852
AN - SCOPUS:4143125552
VL - 22
SP - 3722
EP - 3726
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 27-28
ER -